ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.461,52
-0,89%
S&P 500
5.580,94
-1,97%
Dow Jones
41.583,90
-1,69%
Euro vs US Dollar
1,08845
-0,01%
Bitcoin
83.905,70
-0,53%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) News

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:AIM
DatumZeitQuelleÜberschriftSymbolFirma
27/03/202513h05GlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
27/03/202512h17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:AIMAIM ImmunoTech Inc
18/03/202522h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
18/03/202522h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
18/03/202522h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
11/03/202513h45GlobeNewswire Inc.AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceAMEX:AIMAIM ImmunoTech Inc
06/03/202515h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/03/202516h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
04/03/202521h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
04/03/202520h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
04/03/202520h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
04/03/202519h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
28/02/202522h45Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:AIMAIM ImmunoTech Inc
28/02/202514h45GlobeNewswire Inc.AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaAMEX:AIMAIM ImmunoTech Inc
28/02/202514h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
26/02/202523h23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
26/02/202519h20GlobeNewswire Inc.AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing ComplianceAMEX:AIMAIM ImmunoTech Inc
26/02/202514h45Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
26/02/202514h30GlobeNewswire Inc.AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent DirectorAMEX:AIMAIM ImmunoTech Inc
25/02/202514h30GlobeNewswire Inc.AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
20/02/202522h52Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
20/02/202522h52Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
20/02/202522h52Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
19/02/202522h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
19/02/202522h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
14/02/202522h55Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:AIMAIM ImmunoTech Inc
11/02/202514h50Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
11/02/202514h45GlobeNewswire Inc.AIM ImmunoTech Releases Virtual Investor “What This Means Segment”AMEX:AIMAIM ImmunoTech Inc
11/02/202514h35Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
11/02/202514h30GlobeNewswire Inc.AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024AMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM

Kürzlich von Ihnen besucht

NASDAQ
JBLU
JetBlue Airways
MRTX
CYFMUSDT
CyberFM
NASDAQ
CBWBX
Ci Canadian Dividend Cor...
NASDAQ
CCXFX
Ci Doubleline Total Retu...
NASDAQ
SLDP
Solid Power
NASDAQ
FHJXX
Counsel Money Market Ser...
COIN
AXSEUR
Axie Infinity Shard
EU
CO
Casino Guichard Perrachon
BIT
1CS
Axa
NASDAQ
FBSLX
Agf Global Strategic Inc...
EU
VLA
Valneva
NASDAQ
CFRMX
Ci Portfolio Series Cons...
TSX
PPL
Pembina Pipeline
NASDAQ
CBSSX
Ci Canadian Bond Corpora...
NASDAQ
ATYR
aTyr Pharma
NASDAQ
CBXHX
Ci Canadian Equity Corpo...
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten